Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Aggressive B-Cell Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00303953
What this trial is testing

PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell Lymphoma
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Ended earlyNCT00902525
What this trial is testing

Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 25
Testing effectiveness (Phase 2)Looking for participantsNCT05826535
What this trial is testing

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Lyell Immunopharma, Inc. 270
Testing effectiveness (Phase 2)Looking for participantsNCT06806033
What this trial is testing

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Who this might be right for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche 130
Testing effectiveness (Phase 2)Study completedNCT00884286
What this trial is testing

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

Who this might be right for
LeukemiaLymphoma
PharmaMar 67
Testing effectiveness (Phase 2)Active Not RecruitingNCT02436707
What this trial is testing

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Lymphoma
Canadian Cancer Trials Group 129
Not applicableLooking for participantsNCT07059741
What this trial is testing

Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
The First Affiliated Hospital of Soochow University 20
Testing effectiveness (Phase 2)Ended earlyNCT01434472
What this trial is testing

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Post-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+4 more
Fred Hutchinson Cancer Center 20
Testing effectiveness (Phase 2)Ended earlyNCT05588440
What this trial is testing

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Malignancies
Oncternal Therapeutics, Inc 9
Not applicableLooking for participantsNCT06485076
What this trial is testing

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryMultiple Myeloma Stage III+5 more
University Health Network, Toronto 144
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Testing effectiveness (Phase 2)UnknownNCT04553393
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Who this might be right for
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital 80
Early research (Phase 1)Study completedNCT01164709
What this trial is testing

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more
Swiss Cancer Institute 18
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Testing effectiveness (Phase 2)Looking for participantsNCT06536049
What this trial is testing

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+11 more
Yazeed Sawalha 38
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Ended earlyNCT00776373
What this trial is testing

Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

Who this might be right for
ALLBurkitt's LymphomaLymphoblastic Leukemia+1 more
Abramson Cancer Center at Penn Medicine 4
Testing effectiveness (Phase 2)Study completedNCT00588094
What this trial is testing

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Who this might be right for
LymphomaB-cell Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 20
Early research (Phase 1)WithdrawnNCT02875002
What this trial is testing

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Who this might be right for
Relapsed and Refractory Aggressive B- and T-cell LymphomasLymphoma
Yale University
Next Page